Last reviewed · How we verify
intranasal saline solution plus glycerol
Intranasal saline solution with glycerol provides osmotic hydration and mucosal moisturization to the nasal passages.
Intranasal saline solution plus glycerol, marketed by Unidad de Investigacion en Enfermedades Cronico-Degenerativas, holds a niche position in the therapeutic landscape. The key composition patent expiring in 2028 provides a temporary barrier to generic competition, enhancing the drug's market stability. However, the lack of revenue data and primary trial results poses a significant risk in assessing its commercial viability and therapeutic efficacy.
At a glance
| Generic name | intranasal saline solution plus glycerol |
|---|---|
| Also known as | Nasalub |
| Sponsor | Unidad de Investigacion en Enfermedades Cronico-Degenerativas |
| Drug class | Nasal decongestant/mucosal hydration agent |
| Modality | Small molecule |
| Therapeutic area | Otolaryngology/Respiratory |
| Phase | FDA-approved |
Mechanism of action
Saline solution cleanses and irrigates nasal mucosa while glycerol acts as a humectant and osmotic agent, drawing moisture into the nasal tissues and maintaining hydration of the epithelial surface. This combination helps restore normal nasal function, reduce congestion, and support mucosal barrier integrity.
Approved indications
- Nasal congestion and dryness
- Nasal mucosa hydration and cleansing
Common side effects
- Nasal irritation
- Epistaxis (rare)
- Local discomfort
Key clinical trials
- Use of Intranasal Oxytocin During Detoxification of Crack Cocaine (PHASE1, PHASE2)
- Calcitonin in the Treatment of Fibromyalgia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: